Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

Boston Scientific Corp. engages in the development ... The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral ...

Boston Scientific shares fell Wednesday ... by a 25% sales jump of its cardiovascular products to $2.73 billion. The MedSurg division, which includes endoscopy, urology, and neuromodulation ...

Boston Scientific had increased its debt leverage to acquire new products in 2015-16 and reduced ... electrophysiology, endoscopy, urology, neuromodulation, and other interventional cardiology ...

Boston Scientific had increased its debt leverage to acquire new products in 2015-16 and reduced ... electrophysiology, endoscopy, urology, neuromodulation, and other interventional cardiology ...

Endoscopy Equipment market in terms of revenue was estimated to be worth $32.3 billion in 2024 and is poised to reach $46.2 billion by 2029, growing at a CAGR of 7.4% from 2024 to ...

Investing.com -- Boston Scientific (NYSE:BSX ... also above the $4.04 billion estimated by analysts. Endoscopy net sales were $678 million, a 7.8% year-over-year increase, slightly above the ...